“We founded Arisaph because its approach to drug discovery was innovative and far-reaching and, in time, would yield differentiated medicines that represent significant advancements for treating many diseases.”
– William Bachovchin, Christopher Kiritsy and Michael Jaharis: Co-Founders
Arisaph Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing novel therapies for cancer, cardiovascular disease and diabetes. The company utilizes proprietary drug discovery platforms to develop differentiated medicines that are highly potent and act selectively on validated targets. Arisaph currently has seven active drug discovery programs in various stages of development.